Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Membrane-targeted complement inhibitors.

G P Smith1, R A Smith

  • 1Adprotech, Chesterford Research Park, Little Chesterford, Saffron Walden, Essex, CB10 1XL, UK. geoff.smith@adpro.co.uk

Molecular Immunology
|September 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cutaneous manifestations of small fibre polyneuropathy.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Analysis of US Food and Drug Administration Warning Letters within dermatological care products.

Clinical and experimental dermatology·2021
Same author

Evaluation of malignancy risk in scleroderma by antibody profile.

The British journal of dermatology·2020
Same author

Analysis of the first 5 years of an interdisciplinary Rheumatology-Dermatology clinic.

Clinical and experimental dermatology·2020
Same author

Development of an auxotrophic, live-attenuated Brucella suis vaccine strain capable of expressing multimeric GnRH.

Vaccine·2019
Same author

Mycobacterium tuberculosis and whole-genome sequencing: how close are we to unleashing its full potential?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same journal

Neutrophil elastase-SERPINB1 axis in epithelial responses: Cell death, inflammation and SERPINB1 dynamics.

Molecular immunology·2026
Same journal

Phillyrin alleviates pulmonary fibrosis via modulation of the TGF-β1/Smad and Nrf2/HO-1 signaling pathways.

Molecular immunology·2026
Same journal

m6A modification of LINC00458 enhances HMOX1 stability via ELAVL1 recruitment to promote ferroptosis and aggravate asthma.

Molecular immunology·2026
Same journal

Overexpression of Hes1 inhibits cigarette smoke-induced mitochondrial apoptosis in AT2 cells by activating the Pgc-1α/Tfam signaling pathway.

Molecular immunology·2026
Same journal

Progesterone promotes favorable pregnancy outcomes in recurrent spontaneous, abortion by attenuating NK Cell overactivation and upregulating the cAMP/PKA/CREB signaling axis.

Molecular immunology·2026
Same journal

Oleanolic acid alleviates hepatic fibrosis by inhibiting liver macrophage recruitment and polarization.

Molecular immunology·2026
See all related articles

Targeting complement regulator proteins to cell membranes improves therapeutic efficacy for diseases driven by complement activation. Engineered proteins show promise, with one inhibitor entering clinical trials for various conditions.

Area of Science:

  • Immunology
  • Biotechnology
  • Pathology

Background:

  • Undesirable complement activation causes tissue damage and inflammation in numerous human diseases.
  • Complement-mediated damage results from complement component deposition on cell surfaces.
  • Current strategies aim to target complement regulator proteins to cell membranes.

Purpose of the Study:

  • To review strategies for targeting complement regulator proteins to cell membranes.
  • To highlight the development of engineered proteins as complement inhibitors.
  • To discuss the therapeutic potential of membrane-targeted complement inhibitors.

Main Methods:

  • Review of existing strategies for membrane-targeting of complement regulators.
  • Analysis of in vitro potency and in vivo efficacy in animal models.

Related Experiment Videos

  • Examination of clinical development status of membrane-targeted complement inhibitors.

    • Main Results:

    • Engineered proteins demonstrate improved potency in vitro.
    • Enhanced therapeutic benefits observed in animal models of disease.
    • One membrane-targeted complement inhibitor has advanced to clinical development.

    Conclusions:

    • Membrane-targeted complement inhibition represents a promising therapeutic strategy.
    • Second-generation complement inhibitors may offer effective treatments for various diseases.
    • Clinical development of these agents indicates significant therapeutic potential.